# Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

## TL;DR

A 40-year-old man with a rare condition called eosinophilic fasciitis improved after treatment with rituximab and IVIG when standard treatments failed.

## Contribution

This case report suggests rituximab and IVIG may be effective for refractory eosinophilic fasciitis.

## Key findings

- Standard treatments failed for the patient with eosinophilic fasciitis.
- The patient showed improvement after receiving rituximab and IVIG.
- Further studies are needed to confirm the effectiveness and safety of rituximab for EF.

## Abstract

Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.